NCT05303857View on ClinicalTrials.gov

Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

December 15, 2023

Study Completion Date

April 17, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide Pen Injector

Injection of the semaglutide once weekly

DRUG

Placebo

Injection of placebo once weekly

Trial Locations (1)

91054

Clinical Research Center, Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER